Perlmutter Cancer Center

The purpose of the study is to determine if the administration of the investigational prophylactic medications: PTCy, bortezomib and abatacept, for individuals with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation (HSCT) peripheral blood stem cell (PBSC) transplant, is effective in the prevention of graft versus host disease (GvHD) and allows prompt immune reconstruction.

The study drugs are cytoxan, bortezomib and abatacept are investigational, which means that they have not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test these agents in the current trial.